Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial

Rajiv Agarwal, Pooneh Alborzi, Sangeetha Satyan, Robert P Light, Rajiv Agarwal, Pooneh Alborzi, Sangeetha Satyan, Robert P Light

Abstract

Volume excess is thought to be important in the pathogenesis of hypertension among hemodialysis patients. To determine whether additional volume reduction will result in improvement in blood pressure (BP) among hypertensive patients on hemodialysis and to evaluate the time course of this response, we randomly assigned long-term hypertensive hemodialysis patients to ultrafiltration or control groups. The additional ultrafiltration group (n=100) had the dry weight probed without increasing time or duration of dialysis, whereas the control group (n=50) only had physician visits. The primary outcome was change in systolic interdialytic ambulatory BP. Postdialysis weight was reduced by 0.9 kg at 4 weeks and resulted in -6.9 mm Hg (95% CI: -12.4 to -1.3 mm Hg; P=0.016) change in systolic BP and -3.1 mm Hg (95% CI: -6.2 to -0.02 mm Hg; P=0.048) change in diastolic BP. At 8 weeks, dry weight was reduced 1 kg, systolic BP changed -6.6 mm Hg (95% CI: -12.2 to -1.0 mm Hg; P=0.021), and diastolic BP changed -3.3 mm Hg (95% CI: -6.4 to -0.2 mm Hg; P=0.037) from baseline. The Mantel-Hanzel combined odds ratio for systolic BP reduction of > or =10 mm Hg was 2.24 (95% CI: 1.32 to 3.81; P=0.003). There was no deterioration seen in any domain of the kidney disease quality of life health survey despite an increase in intradialytic signs and symptoms of hypotension. The reduction of dry weight is a simple, efficacious, and well-tolerated maneuver to improve BP control in hypertensive hemodialysis patients. Long-term control of BP will depend on continued assessment and maintenance of dry weight.

Trial registration: ClinicalTrials.gov NCT00067665.

Figures

Figure 1
Figure 1
Enrollment and Trial flow.
Figure 2
Figure 2
The effect of dry-weight reduction on interdialytic ambulatory systolic (Panel A) and diastolic blood pressure (Panel B) in hypertensive hemodialysis patients. The mean systolic and diastolic blood pressures are shown for the baseline control and ultrafiltration groups. The mean changes in blood pressure are shown for weeks 4 and 8 following randomization (solid arrows), and the mean differences in blood pressures (dotted arrows) between the two groups at each 4 week interval. The numbers next to the dotted lines connecting the data points are the mean changes in blood pressure between groups at 4 and 8 weeks following randomization. The 95% confidence intervals are given in parentheses. Asterisks (p

Figure 3

Relationship of change in systolic…

Figure 3

Relationship of change in systolic ambulatory blood pressure with ultrafiltration compared to the…

Figure 3
Relationship of change in systolic ambulatory blood pressure with ultrafiltration compared to the change in post-dialysis weight. Changes depict the reduction in systolic blood pressure at 4 weeks (circles) and 8 weeks (triangles) from baseline plotted against changes in post-dialysis weight at 4 weeks and at 8 weeks. Regression lines reflect the linear relationships at 4 weeks (blue line) and at 8 weeks (green line)

Figure 4

Reduction in systolic ambulatory blood…

Figure 4

Reduction in systolic ambulatory blood pressure with ultrafiltration compared to the control group.…

Figure 4
Reduction in systolic ambulatory blood pressure with ultrafiltration compared to the control group. Changes depict the reduction in systolic blood pressure at 4 weeks (grey circles) and 8 weeks (brown circles) and their 95% confidence intervals. Only the interaction between ultrafiltration and race was significant (p=0.01). The size of the circles is proportional to the number of patients.
Figure 3
Figure 3
Relationship of change in systolic ambulatory blood pressure with ultrafiltration compared to the change in post-dialysis weight. Changes depict the reduction in systolic blood pressure at 4 weeks (circles) and 8 weeks (triangles) from baseline plotted against changes in post-dialysis weight at 4 weeks and at 8 weeks. Regression lines reflect the linear relationships at 4 weeks (blue line) and at 8 weeks (green line)
Figure 4
Figure 4
Reduction in systolic ambulatory blood pressure with ultrafiltration compared to the control group. Changes depict the reduction in systolic blood pressure at 4 weeks (grey circles) and 8 weeks (brown circles) and their 95% confidence intervals. Only the interaction between ultrafiltration and race was significant (p=0.01). The size of the circles is proportional to the number of patients.

References

    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
    1. Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, Bakris GL. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121:332–340.
    1. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291–297.
    1. Agarwal R. Assessment of blood pressure in hemodialysis patients. Semin Dial. 2002;15:299–304.
    1. Converse RL, Jr, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–1918.
    1. Andersen MJ, Agarwal R. Etiology and management of hypertension in chronic kidney disease. Med Clin North Am. 2005;89:525–547.
    1. Wilson J, Shah T, Nissenson AR. Role of sodium and volume in the pathogenesis of hypertension in hemodialysis. Semin Dial. 2004;17:260–264.
    1. Dorhout Mees EJ. Volaemia and blood pressure in renal failure: have old truths been forgotten? Nephrol Dial Transplant. 1995;10:1297–1298.
    1. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH. Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet. 1967;2:69–73.
    1. Lins RL, Elseviers M, Rogiers P, Van Hoeyweghen RJ, De Raedt H, Zachee P, Daelemans RA. Importance of volume factors in dialysis related hypertension. Clin Nephrol. 1997;48:29–33.
    1. Fagugli RM, Pasini P, Quintaliani G, Pasticci F, Ciao G, Cicconi B, Ricciardi D, Santirosi PV, Buoncristiani E, Timio F, Valente F, Buoncristiani U. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant. 2003;18:2332–2338.
    1. Sanders PW. Assessment and treatment of hypertension in dialysis: the case for salt restriction. Semin Dial. 2007;20:408–411.
    1. Lazarus JM, Hampers C, Merrill JP. Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med. 1974;133:1059–1066.
    1. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med. 1969;280:978–981.
    1. Krautzig S, Janssen U, Koch KM, Granolleras C, Shaldon S. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant. 1998;13:552–553.
    1. Toz H, Ozkahya M, Ozerkan F, Asci G, Ok E. Improvement in “uremic” cardiomyopathy by persistent ultrafiltration. Hemodial Int. 2007;11:46–50.
    1. Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, Mees EJ. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol. 2002;15:655–660.
    1. Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: Importance of the lag phenomenon. Am J Kidney Dis. 1998;32:720–724.
    1. Charra B, Calemard E, Ruffet M, Chazot C, Terrat J-C, Vanel T, Laurent G. Survival as an index of adequacy of dialysis. Kidney Int. 1992;41:1286–1291.
    1. Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre and post dialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2006;1:389–398.
    1. Charra B, Laurent G, Chazot C, Calemard E, Terrat JC, Vanel T, Jean G, Ruffet M. Clinical assessment of dry weight. Nephrol Dial Transplant. 1996;11(Suppl 2):16–19.
    1. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol. 1999;10:392–403.
    1. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3:329–338.
    1. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF., Jr Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548–1555.
    1. van Brummelen P, Woerlee M, Schalekamp MA. Long-term versus short-term effects of hydrochlorothiazide on renal haemodynamics in essential hypertension. Clin Sci. 1979;56:463–469.
    1. Frohlich ED, Schnaper HW, Wilson IM, Freis ED. Hemodynamic Alterations in Hypertensive Patients due to Chlorothiazide. N Engl J Med. 1960;262:1261–1263.
    1. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendroflumethiazide, antihypertensive effect, and adverse biochemical effects. Br Med J. 1990;300:975–978.
    1. Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis. 1997;29:383–391.
    1. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291–1299.
    1. Katzarski KS, Charra B, Luik AJ, Nisell J, Divino Filho JC, Leypoldt JK, Leunissen KM, Laurent G, Bergstrom J. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant. 1999;14:369–375.
    1. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, Pratt JH. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481–487.
    1. Agarwal R, Andersen MJ, Pratt JH. On the importance of pedal edema in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:153–158.
    1. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–2194.
    1. Guyton AC, Coleman TG, Cowley AV, Jr., Scheel KW, Manning RD, Jr., Norman RA., Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52:584–594.

Source: PubMed

3
Prenumerera